Erratum: An adenovirus vaccine expressing Ebola virus variant Makona glycoprotein is efficacious in guinea pigs and nonhuman primates (J Infect Dis (2016) 214: 3 (S326-S332) DOI: 10.1093/infdis/jiw250);An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S326-S332

  Wu, Shipo ^a   Kroeker, Andrea ^f,g   Wong, Gary ^b,f,g   He, Shihua ^f,g   Hou, Lihua ^a   Audet, Jonathan ^f,g   Wei, Haiyan ^d   Zhang, Zhe ^a   Fernando, Lisa ^f   Soule, Geoff ^f   Tran, Kaylie ^f   Bi, Shengli ^c   Zhu, Tao ^e   Yu, Xuefeng ^e   Chen, Wei ^a   Qiu, Xiangguo ^f,g  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Institute of Infectious Disease   (China)

^e Tianjin CanSino Biotechnology ^*  (China)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adenovirus virus; Ebola virus; Guinea pigs; Nonhuman primates; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD69 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR; VIRUS GLYCOPROTEIN; ADENOVIRUS VACCINE; EBOLA VACCINE; GLYCOPROTEIN; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GUINEA PIG; HUMORAL IMMUNITY; LEUKOCYTE COUNT; MACACA FASCICULARIS; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; AFRICA; ANIMAL; CENTRAL AFRICA; CHINA; EBOLAVIRUS; GENE VECTOR; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNIZATION; IMMUNOLOGY; PRIMATE; VIROLOGY;

ADENOVIRUS VACCINES; AFRICA, CENTRAL; AFRICA, WESTERN; ANIMALS; CHINA; EBOLA VACCINES; EBOLAVIRUS; GENETIC VECTORS; GLYCOPROTEINS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION; PRIMATES; VIRAL PROTEINS;

EID: 84990890581     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw554     Document Type: Erratum

References (32)

1. WHO. Ebola situation report-17 February 2016. http://apps.who.int/ebola/currentsituation/ebola-situation-report-17-february-2016. Accessed 25 February 2016.
2. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196(suppl 2): S142-7.
3. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
4. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4.
5. Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One 2012; 7:e44115.
6. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014; 20:1126-9.
7. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
8. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88.
9. Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 2013; 87:4952-64.
10. Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathogens 2013; 9:e1003389.
11. Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report. N Engl J Med 2015; 374:1635-46.
12. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebocontrolled phase 1/2 trial. Lancet Infect Dis 2015; 15:1156-66.
13. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13.
14. Marzi A, Robertson SJ, Haddock E, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015; 349:739-42.
15. Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385:2272-9.
16. Marzi A, Falzarano D. An updated Ebola vaccine: immunogenic, but will it protect? Lancet 2015; 385:2229-30.
17. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:158ra46.
18. Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78-83.
19. Radosevic K, Wieland CW, Rodriguez A, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007; 75:4105-15.
20. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006; 12:1596-9.
21. Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway delivery of an adenovirusbased Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013; 87:3668-77.
22. Choi JH, Jonsson-Schmunk K, Qiu X, et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol Pharm 2015; 12:2712-31.
23. Su S, Bi Y, Wong G, Gray GC, Gao GF, Li S. Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza Virus in China. J Virol 2015; 89:8671-6.
24. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177.
25. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(suppl 1):S203-17.
26. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
27. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
28. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998; 221: 35-41.
29. Vu H, Shulenin S, Grolla A, et al. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral Res 2016; 126:55-61.
30. Stat.columbia.edu. Stan: A probabilistic programming language. http://www.stat. columbia.edu/~gelman/research/unpublished/stan-resubmit-JSS1293.pdf. Accessed 28 February 2016.
31. Kruschke JK. Bayesian estimation supersedes the t test. J Exp Psychol Gen 2013; 142:573-603.
32. Finak G, Frelinger J, Jiang W, et al. OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysis. PLoS Comput Biol 2014; 10:e1003806.